Cover Image

Use of dapagliflozin in patients with advanced diabetic kidney disease

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are effective for overweight diabetic patients through the induction of glucosuria. However, SGLT2 inhibitors are not recommended for patients with advanced chronic kidney disease (CKD) because they may aggravate renal function and thus become less e...

Full description

Saved in:

Bibliographic Details
Main Authors:	Hyun Sun Park (Author), Youn Joo Jung (Author), Dong-Young Lee (Author), Kyoung Hyoub Moon (Author), Beom Kim (Author), Hae Won Kim (Author)
Format:	Book
Published:	The Korean Society of Nephrology, 2018-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Dapagliflozin Does Not Protect against Adriamycin-Induced Kidney Injury in Mice
by: Jin Joo Cha, et al.
Published: (2024)

Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors
by: Jong-Mi Seong, et al.
Published: (2021)

A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects
by: Kim HC, et al.
Published: (2023)

Dapagliflozin versus empagliflozin in patients with chronic kidney disease
by: Hilmi Alnsasra, et al.
Published: (2023)

Diagnostic accuracy of urine dipstick for proteinuria in older outpatients
by: Dongmin Lim, et al.
Published: (2014)

Pharmacoeconomic analysis of dapagliflozin in patients with chronic kidney disease and type 2 diabetes in the Russian Federation
by: Sergey V. Nedogoda, et al.
Published: (2024)

Dapagliflozin Ameliorates Diabetic Kidney Disease via Upregulating Crry and Alleviating Complement Over-activation in db/db Mice
by: Dong-Yuan Chang, et al.
Published: (2021)

High-Salt Attenuates the Efficacy of Dapagliflozin in Tubular Protection by Impairing Fatty Acid Metabolism in Diabetic Kidney Disease
by: Meina Zou, et al.
Published: (2021)

Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE study
by: Elisa Lazzaroni, et al.
Published: (2022)

Pharmacokinetics of a Fixed-Dose Combination Product of Dapagliflozin and Linagliptin and Its Comparison with Co-Administration of Individual Tablets in Healthy Humans
by: Jin-Woo Park, et al.
Published: (2022)

Predictive performance of the new race-free Chronic Kidney Disease Epidemiology Collaboration equations for kidney outcome in Korean patients with chronic kidney disease
by: Hyoungnae Kim, et al.
Published: (2023)

Pharmacokinetic and pharmacodynamic drug-drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers
by: Dasohm Kim, et al.
Published: (2023)

Development of Clinically Optimized Sitagliptin and Dapagliflozin Complex Tablets: Pre-Formulation, Formulation, and Human Bioequivalence Studies
by: So-Jin Kang, et al.
Published: (2023)

Clinical and economic analysis of using dapagliflozin in patients with chronic kidney disease in the Russian Federation
by: Sergey V. Nedogoda, et al.
Published: (2021)

Nondiabetic kidney diseases in type 2 diabetic patients
by: Ye Jin Kim, et al.
Published: (2013)

Novel biomarkers for diabetic kidney disease
by: Chan-Young Jung, et al.
Published: (2022)

Blood pressure control in diabetic kidney disease: a post-hoc analysis of the FANTASTIC trial
by: Cheol Ho Park, et al.
Published: (2024)

Preferences for Advance Directives in Korea
by: So-Sun Kim, et al.
Published: (2012)

Improved Manufacturability and In Vivo Comparative Pharmacokinetics of Dapagliflozin Cocrystals in Beagle Dogs and Human Volunteers
by: Sangho Cho, et al.
Published: (2021)

Estimating baseline creatinine values to define acute kidney injury in critically ill pediatric patients
by: Yeon Joo Lee, et al.
Published: (2022)

Acute Kidney Injury and Electrolyte Imbalances Caused by Dapagliflozin Short-Term Use
by: António Cabral Lopes, et al.
Published: (2024)

Inhibition of Sodium-GlucoseCotransporter 2 with Dapagliflozin in Han: SPRD Rats with Polycystic Kidney Disease
by: Daniel Rodriguez, et al.
Published: (2015)

The Association between Dapagliflozin Use and the Risk of Post-Contrast Acute Kidney Injury in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Propensity-Matched Analysis
by: Tao Liu, et al.
Published: (2023)

The expression of two isoforms of matrix metalloproteinase-2 in aged mouse models of diabetes mellitus and chronic kidney disease
by: Harin Rhee, et al.
Published: (2018)

Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes
by: Papakitsou I, et al.
Published: (2019)

Dapagliflozin for the treatment of type 2 diabetes: a review of the literature
by: Saeed MA, et al.
Published: (2014)

Poor Glycemic Control Can Increase the Plasma Kidney Injury Molecule-1 Concentration in Normoalbuminuric Children and Adolescents with Diabetes Mellitus
by: Moon Bae Ahn, et al.
Published: (2021)

The Prenatal and Postnatal Incidence of Congenital Anomalies of the Kidneys and Urinary Tract (CAKUT) Detected by Ultrasound
by: Hyun Ah Choi, et al.
Published: (2016)

Diabetic Kidney Disease: Challenges, Advances, and Opportunities
by: Ya Chen, et al.
Published: (2020)

A case of biopsy-proven chronic kidney disease on progression from acute phosphate nephropathy
by: Woo Chul Joo, et al.
Published: (2012)

Prolonged Ketosis in a Patient With Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin
by: Shreya Pujara MD, et al.
Published: (2017)

The successful clinical outcomes of pregnant women with advanced chronic kidney disease
by: Ji-Yeun Chang, et al.
Published: (2016)

Chronic Administration of Visfatin Ameliorated Diabetic Nephropathy in Type 2 Diabetic Mice
by: Young Sun Kang, et al.
Published: (2016)

Framingham risk score and risk of incident chronic kidney disease: A community-based prospective cohort study
by: Changhyun Lee, et al.
Published: (2019)

Association between Oral Health and Gastric Neoplastic Lesions
by: Jae Hwang Cha, et al.
Published: (2018)

Excessively Enlarged Mitochondria in the Kidneys of Diabetic Nephropathy
by: Kiyoung Kim, et al.
Published: (2021)

Metformin treatment for patients with diabetes and chronic kidney disease: A Korean Diabetes Association and Korean Society of Nephrology consensus statement
by: Kyu Yeon Hur, et al.
Published: (2020)

Frequency of Fabry disease in chronic kidney disease patients including patients on renal replacement therapy in Korea
by: Eunjung Cho, et al.
Published: (2024)

Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide
by: Maria Elena Lunati, et al.
Published: (2024)

Dapagliflozin: A new hope for the therapeutic treatment of type 2 diabetes mellitus
by: Naazneen Maksud, et al.
Published: (2024)